US Patent

US10206932 — Natural combination hormone replacement formulations and therapies

Method of Use · Assigned to TherapeuticsMD Inc · Expires 2032-11-21 · 7y remaining

Vulnerability score 45/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects pharmaceutical compositions for co-administering estradiol and progesterone to a human subject.

USPTO Abstract

Pharmaceutical compositions for co-administering estradiol and progesterone to a human subject in need thereof are provided. In some embodiments, the pharmaceutical composition comprises solubilized estradiol, suspended progesterone, and a solubilizing agent comprising a medium chain (C6-C12) oil.

Drugs covered by this patent

Estrace (ESTRADIOL) · Pfizer

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2439`	—	Estrace
`U-2439`	—	Estrace

Patent Metadata

Patent number: US10206932
Jurisdiction: US
Classification: Method of Use
Expires: 2032-11-21
Drug substance claim: No
Drug product claim: No
Assignee: TherapeuticsMD Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.